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Abstract
Primary sclerosing cholangitis (PSC) is a chronic disease of the bile ducts characterized by an inflammatory infiltrate and
obliterative fibrosis. The precise role of the immune system in the pathogenesis of PSC remains unknown. We used RNA
microarray analysis to identify immune-related genes and pathways that are differentially expressed in PSC. Messenger RNA
(mRNA) from peripheral blood mononuclear cells (PBMC) was isolated from both patients with PSC and age and sex
matched healthy controls. Samples from 5 PSC patients and 5 controls were analyzed by microarray and based upon rigorous
statistical analysis of the data, relevant genes were chosen for confirmation by RT-PCR in 10 PSC patients and 10 controls.
Using unsupervised hierarchical clustering, gene expression in PSC was statistically different from our control population.
Interestingly, genes within the IL-2 receptor beta, IL-6 and MAP Kinase pathways were found to be differently expressed in
patients with PSC compared to controls. Further, individual genes, TNF-a induced protein 6 (TNFaip6) and membrane-
spanning 4-domains, subfamily A (ms4a) were found to be upregulated in PSC while similar to Mothers against
decapentaplegic homolog 5 (SMAD 5) was downregulated. In conclusion, several immune-related pathways and genes were
differentially expressed in PSC compared to control patients, giving further evidence that this disease is systemic and immune-
mediated.
Keywords: Microarray, TNF-a induced protein 6 (TNFaip6), membrane-spanning 4-domains subfamily A (ms4a), similar
to mothers against decapentaplegic homolog 5 (SMAD 5)
Introduction
Primary sclerosing cholangitis (PSC) is a rare liver
disease of chronic inflammation affecting primarily
medium and large sized bile ducts leading to fibrosis
and eventually cirrhosis. Histologically, PSC is
characterized by an inflammatory infiltrate and
obliterative fibrosis, which leads to the pathognomic
biliary strictures observed on cholangiographic
imaging. Whether this immune response is auto-
immune in nature or simply a response to bacterial or
viral pathogens remains unresolved.
Several lines of evidence have established that PSC
is an immune-mediated process. First, the inflam-
matory infiltrate of PSC consists predominantly of T
cells, which have been shown to have a Th-1 type
phenotype. Second, patients with PSC and their
family members have increased frequencies of
autoimmune diseases (Saarinen et al. 2000; Bergquist
et al. 2005), for example, approximately 80% of
patients with PSC have coexistent inflammatory
bowel disease (IBD), most often ulcerative colitis
(Schrumpf and Boberg 2001; Bambha et al. 2003).
Third, the human leukocyte antigen (HLA) complex,
particularly the HLA B8-DR3 haplotype, has been
positively associated with PSC (Schrumpf et al. 1982;
Chapman et al. 1983; Spurkland et al. 1999;
Donaldson and Norris 2001; Wiencke et al. 2001;
Bittencourt et al. 2002; Neri et al. 2003). Finally,
autoantibodies are frequent in PSC, the most
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common is the atypical perinuclear anti-neutrophil
antibody (p-ANCA), present in 80% of patients
(Terjung and Worman 2001; Aoki et al. 2005b). The
purpose of this study was to compare the gene
expression profile of peripheral blood mononuclear
cells (PBMC) from PSC patients with age and sex
matched controls using microarray technology.
Materials and methods
Subjects
The PSC patients were clinically well characterized
and diagnosed in accordance with accepted criteria
with typical findings at cholangiography (Chapman
et al. 1980; Wiesner and LaRusso 1980), the diagnosis
and classification of IBD were based on endoscopic
and histological criteria. Demographic and clinical
characteristics of the patients are noted in Table I.
Unrelated, healthy, age and sex matched controls were
used throughout this study. The study protocol
conformed to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a priori approval
by the appropriate institutional review committee.
Informed consent in writing was obtained from each
subject.
RNA isolation
Heparinized venous blood samples were obtained and
within 1 h of collection, PBMC isolated by Ficoll-
Histopaque gradient centrifugation techniques using
Histopaque-1077 (Sigma Chemical Co, St Louis,
MO, USA). Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) was used to isolate total RNA, the RNA
quality and integrity was determined using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA) and absorbance at A260/A280.
Microarray analysis
In the first part of this study, five PSC subjects (PSC 1,
3, 4, 5 and 7) and matched controls were used for
microarray analysis. Sample labeling, hybridization to
chips and image scanning were performed as
described (Affymetrix Expression Analysis Technical
Manual). For each sample, 10mg total RNA was
labeled using One-Cycle Target Labeling and hybri-
dized to the Affymetrix Human U133 Plus2 arrays
that contain more that 54,000 probe sets that sample
over 39,000 genes.
Data analysis
The ten CEL files were first imported into the R
environment and analysed with the Affymetrixw
package of Bioconductor. Raw data were normalized
with quantile normalization; background corrected
and gene expression levels computed with Robust
Multichip Average (RMA) (http://www.bioconductor.
org/). Presence/absence calls were computed using
the Wilcoxon signed rank-based gene expression
presence/absence detection algorithm. Genes present
with a p , 0.005 significance level were included for
further analysis. Significant differences between PSC
and control groups were computed using Student
t-test for genes that differed at least 2-fold between the
medians of the cases and controls. A p-value of
p , 0.005 was considered significant. Genes that were
expressed in at least 80% of the samples and had a
2-fold or greater difference compared to the median
of the samples were clustered using unsupervised
hierarchical clustering with Gene Cluster 3.0. The
leaves of the clustering trees were then folded with
Self-Organizing Map (SOM) algorithm. The cluster-
ing result was presented using Java TreeView 1.0.1.
Semi-quantitative RT-PCR
For the second part of our study, mRNA from 10
PSC patients and 10 aged and sex matched controls
were used for RT-PCR. Gene microarray results
were validated for a select number of transcripts
using semi-quantitative real-time polymerase chain
reaction (Table II) performed on 1ml of a 1:10
dilution of the cDNA reaction was used for template
with primers in a 25-ml SYBR Green Assay
Table I. Characteristics of patients with PSC.
PSC Patients Age (y) Sex Co-morbidities Relevant medications Disease duration (years) Disease stage
1 56 Female UC UDCA/mesalamine 5 Unknown
2 55 Female UC UDCA 10 Grade I
3 26 Female UC Vancomycin 2 Grade II
4 60 Male UC Folic acid 10 Cirrhosis
5 32 Male None UDCA 12 Cirrhosis
6 39 Female None UDCA 4 Grade III
7 58 Male CD Mesalamine 1 None
8 33 Female CD, Sacroilitis None 10 Cirrhosis
9 56 Male None None 4 Cirrhosis
10 46 Male None UDCA 13 Cirrhosis
UC, ulcerative colitis; CD, Crohn’s disease; UDCA, ursodeoxycholic acid.
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(PE Biosystems, Foster City, CA, USA) reaction.
Cycling consisted of one-cycle at 508C for 2 min, one-
cycle at 958C for 2 min, and 40 cycles of 958C for 15 s
and 608C for 1 min on an ABI 7700 Sequence
Detector (PE Biosystems, Foster City, CA, USA).
GAPDH RNA was also measured using primers
GAPDH.F (50-GAAGGTGAAGGTCGGAGTC-30)
and GAPDH.R (50-GAAGATGGTGATGGGA-
TTTC-30). All samples were assayed in duplicate.
Quantification was performed using Sequence
Figure 1. Unsupervised hierarchical clustering differentiated the gene expression arrays from 5 PSC patients and 5 age- and sex-matched
controls. Two oligo sets for the TNFAIP6 gene are shown. Gene expressions with higher than median values are shown in red, those with lower
than median values are shown in green. Gene expression values found missing are labeled gray.
Table II. Genes chosen for confirmation by RT-PCR and their primer sequences.
Genes Affymetrix probe ID Forward primer sequence Reverse primer sequence
NFKB N.A. GGCAGCAAATAGACGAGCTCC CGCCGCTGTCGCAGAC
Sara1a 210790_s_at TTCCAACACTACATCCGACATCA AGGTCATTCCAGCAATTGTTAGCT
Smad 5 205187_at CAGCAAGTTCTGGACCAGGAA GGAGGCGTATCAGCTGGGA
Smad 4 1565703_at CCGGACATTACTGGCCTGTT AAATGGGAGGCTGGAATGC
TGFBRI 206943_at CCTGGCTAGAGAAGCACAAAAAGTAT AATGATAGAGCAGTCCAAGTGCAA
TNFaip6 206026_s_at ACAACCCACACGCAAAGGAG TTTGGGAAGCCTGGAGATTTAA
Msa4a 1555728_a_at GGATCCTTGTCAATTGCAGCA TCGGACCAGGCCTTTTGTAGT
Hmtp1 216069_at TGAGGTAAGCATTGCCCTAA ATTGAACCAGCCTTGCATTC
IREBP2 1563130_a_at GCATAACCTTTGGCACTTCAA TCATCTTTTGAAGCCAAGCA
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Detector version 1.7 software. A standard curve was
established with pooled cDNA derived from the age
and sex matched controls and used as a calibrator in
each assay. mRNA was recorded relative to the
standard and normalized to GAPDH. Statistical
analysis was performed using Graphpad Prism v 4.0
(Graphpad Inc, San Diego, CA, USA). Because the
distribution was non-Gaussian, comparisons were
made with non-parametric methods. A P value of less
than 0.05 was considered significant.
Results
Unsupervised hierarchical clustering separated PSC
cases from controls (Figure 1). 1887 genes were
clustered that were expressed in at least 80% of the
samples with at least one of the samples having a
2-fold difference in expression compared to the
median of the samples. Using a t-test comparison we
identified 942 genes differentially expressed in
patients with PSC compared to controls when
significance was set at p , 0.005. Using the Database
for Annotation and Visual Integration Discovery
(DAVID) on these 942 genes we found evidence of
several pathways potentially altered in PSC (Table III).
These pathways included IL-2 receptor beta acti-
vation of T cells, IL-6 signaling, macrophage
differentiation by M-CSF and MAP kinase-signaling
pathways. We discovered in PSC PBMC three genes
expressed greater than 2-fold and 18 genes expressed
less than 0.5-fold the median expression index of the
controls (Tables III, IV and V).
To validate the microarray data and to investigate
potential pathways suggested by the array data, we
chose nine genes to quantify by RT-PCR in10 PSC
cases and 10 controls (Figure 2). Of the genes with
greater than 2-fold expression in PSC by microarray,
membrane-spanning 4-domains subfamily A member
4 and tumor necrosis factor alpha-induced protein six
were found to be expressed significantly greater in
PSC by RT-PCR. SMAD 5, which was 0.6-fold less
than controls by microarray at a P value of 0.00003,
was found to be significantly lower in PSC than
controls. However, SMAD 4 and TGF-b receptor
I which signals through SMAD 4 and SMAD 5 were
not found to be significantly different between PSC
and controls. No other genes tested were found to
have statistically significant differences between PSC
patients and controls by RT-PCR (data not shown).
Discussion
Using microarray technology, we screened PBMC
from PSC patients in search of genes that might lead
to insights in the pathophysiology of PSC. We chose to
analyse this data with maximum sensitivity using a
simple t-test and fold change comparison to the
median of the control sample. From this data we then
sought to determine immunological pathways that
may be relevant to the disease. Analysis of the results
suggested the involvement of the IL-2 receptor beta
activation of T cells and IL-6 signaling. The IL-2
receptor is composed of the alpha, beta and gamma
subunit (Leonard et al. 1984). In addition to resting
and activated T cells, the IL-2 receptor beta has been
found on B cells (Zola et al. 1991), natural killer cells
(Nishikawa et al. 1990), monocytes (Espinoza-
Delgado et al. 1990), dendritic epidermal cells
(Tanaka et al. 1992) and neutrophils (Djeu et al.
1993). IL-2 receptor beta knock out mice develop an
increase in activated CD4þT cells, an increase in total
IgG, high-titers of anti-nuclear and anti-DNA
autoantibodies, and an autoimmune hemolytic
anemia. Interestingly, these mice also have an
autoimmune mediated liver disease with immature
myeloid cell infiltration of the liver sinusoids and
portal tracts (Suzuki et al. 1995). The differentially
expressed genes in this pathway found in patients with
PSC may reflect a downregulation of the IL-2 receptor
beta and potentially plays a role in the development of
inflammation of the medium and large bile ducts
observed in PSC.
The reduced expression of SMAD 5 in PSC may be
relevant as a number of autoimmune diseases
Table III. Potential pathways that may be disrupted in patients
with PSC based on the gene expression profiles of PBMC.
Pathway/gene (accession) Fold-change p-value
IL-2 receptor beta activation of T cells
JAK3 1.6 0.002
SOCS3 1.4 0.001
BCL2 1.2 0.002
PPIA 0.8 0.004
CFLAR 0.6 0.001
IL-6 signaling
JAK3 1.6 0.002
STAT3 1.2 0.002
SHP2 0.8 0.001
IL6RB 0.7 0.002
Table IV. Genes with the highest fold difference in expression in
PSC compared to controls when analyzed by t-test and fold change
compared to median of the control samples.
Gene and
affymetrix ID Fold p-value
219607_s_at
j membrane-spanning
4-domains, subfamily A,
member 4
3.33 0.005
202887_s_at j DNA-damage-
inducible transcript 4
2.83 0.002
202912_at j adrenomedullin 2.45 0.0004
206026_s_at j tumor necrosis
factor, alpha-induced protein 6
2.37 0.005
228325_at j KIAA0146 protein 2.35 0.001
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including IBD have been reproduced in TGFb knock
out mice (Hahm et al. 2001; Aoki et al. 2005a). TGFb
has immunosuppressive properties that are mediated
by SMAD signaling.
Other genes confirmed to be differentially expressed
in PSC compared to control include TNF-a induced
protein 6 (TNFaip6) and membrane-spanning
4-domains, subfamily A (ms4a). TNFaip6 is a 35
kilodalton (kda) protein that is elevated in a number of
autoimmune diseases including, systemic lupus
erythematosus, rheumatoid arthritis (Wisniewski and
Vilcek 1997) and mucosal smooth muscle cells in IBD
(Wisniewski and Vilcek 1997). TNFaip6 is a secreted
protein (Lee et al. 1992) found also on PBMC after
stimulation with LPS, TNFa, PHA and Con A, but is
not present on PBMC from healthy human subjects
(Lee et al. 1993; Wisniewski et al. 1993). TNFaip6
is believed to contribute to chronic inflammation in a
Figure 2. Confirmatory RT-PCR using cDNA derived from PBMC from patients with PSC compared to age- and sex-matched healthy
control patients. Each gene is normalized to GAPDH and relative to pooled cDNA from the controls. The horizontal line represents the mean
expression.
Table V. Genes with the lowest fold difference in PSC patients when compared to controls when analyzed by t-test and fold change compared
to the median of the control samples.
Gene and affymetrix ID Fold p-value
209728_at j major histocompatibility complex, class II, DR beta 4 0.026 0.00000003
215666_at j major histocompatibility complex, class II, DR beta 4 0.101 0.0004
243037_at j far upstream element (FUSE) binding protein 1 0.398 0.0007
1563130_a_at j iron-responsive element binding protein 2 0.439 0.00006
235547_at j phosphonoformate immuno-associated protein 5 0.444 0.0009
216069_at j HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) 0.455 0.00005
233940_at j echinoderm microtubule associated protein like 4 0.463 0.004
243751_at j NA 0.464 0.003
229413_s_at j ring finger protein 3 0.471 0.002
215586_at j protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta) 0.473 0.0008
242894_at j NA 0.477 0.002
236353_at j NA 0.478 0.004
230742_at j RNA binding motif protein 5 0.479 0.002
226085_at j chromobox homolog 5 (HP1 alpha homolog, Drosophila) 0.481 0.004
242144_at j PAP associated domain containing 4 0.485 0.002
239258_at j phosphatidylinositol glycan, class F 0.489 0.004
1557270_at j NA 0.491 0.001
244219_at j Wilms tumor 1 associated protein 0.494 0.00003
NA, transcript with no known gene.
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number of ways. First, secreted TNFaip6 complexes
with a serine protease inhibitor, inter-alpha-inhibitor
(Wisniewski et al. 1994), these complexes have been
found in the synovial fluid of rheumatoid arthritis
patients and tightly bind hyaluronic acid (HA), a
major component of extra cellular matrix tissue. The
formation of the TNFaip6:inter-alpha-inhibitor may
play a role in disease by binding to HA and cause a
dysregulation of extracellular matrix remodeling or
assembly (Milner and Day 2003). This may be
occurring in the extracellular matrix of PSC patients
where there is a chronic fibrosing process surrounding
biliary epithelial cells, resulting in an “onion skin” like
appearance on histopathology. Alternatively, the
upregulation of TNFaip6 on PBMC in patients with
PSC may be a marker of intense TNFa or IL-1
stimulation and is acting to inhibit the inflammatory
process as has been shown in air pouch mice, a mouse
model of arthritis (Wisniewski et al. 1996).
MSa4a is a member of a superfamily of which
includes CD20, a marker of precursor and mature B
cells, high affinity IgE receptor (Fc1R1b) found on
mast cells and basophils, and a hematopoietic-cell
specific protein found on a diverse group of myeloid
and lymphoid cells (HTm4) of unknown function
(Ishibashi et al. 2001). These proteins share 16–32%
homology and their genes are all found on chromo-
some 11q12–13.1 (Tedder et al. 1988; Hupp et al.
1989; Adra et al. 1994). Interestingly, this gene has
been mapped to a susceptibility locus in patients with
asthma/atopy (Adra et al. 1999). The MSa4a is more
closely related to Htm4 and Fc1R1b than CD 20 and
found on a number of human lymphoblastoid
cell lines, but more highly expressed in pre B cell
(NALM-6) and B cell lines (BJAB) than T cell lines
(Liang and Tedder 2001). This may confirm prior
reports, which have shown B cells to be the
predominant cell type in PBMC in patients with
PSC (Lindor et al. 1987). The function of the Msa4a
protein is unknown but given its amino acid homology
to the other members of the superfamily it is suggested
it is a component of an oligomeric cell surface complex
that plays a role in signal transduction (Liang and
Tedder 2001).
A number of other candidate genes remain to be
examined further using RT-PCR. We have initially
chosen only those thought to be immunologically
relevant; for many of the genes differentially
expressed, the function remains to be identified.
In addition, further work needs to be performed, to
define the cell type and protein expression of the
identified genes. There has been one other study
looking at genome wide expression in autoimmune
liver disease (Shackel et al. 2001). RNA was extracted
from liver biopsies of patients with PBC (n ¼ 6), PSC
(n ¼ 4) and normal liver and the cDNA array used
consisted of 588 genes and nine housekeeping genes.
None of the genes differentially expressed in that study
were identified in this present study. This lack of
correlation may be related to the different tissue and
gene chip used in that prior study. Our demonstration
of several immune-related pathways and genes
differentially expressed in PSC PBMC compared to
control patients, suggests that the disease is more than
a local inflammatory process in the liver and reflects a
systemic immune response.
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